ClinicalTrials.gg
CompletedNCT02112175ARUMMUpdated Apr 14, 2021

Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM

A Phase 3 interventional study of Lenalidomide in Multiple Myeloma, sponsored by Celgene. Completed at 73 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-14.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
46
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 249 studies testing lenalidomide in Multiple Myeloma — 29 open to participants now, 70 under way, 14 of them phase 3. Lenalidomide · Multiple Myeloma.

Enrollment
131st of 249
46 · median 50
Started
2014
with 9 others
Phase 3
44 of 249
3 open now
Registered
128th of 249
by date
Lead sponsor
14 of 249
Celgene

Among the 249 studies testing lenalidomide in Multiple Myeloma, this one is the 131st largest by enrollment, is one of 10 that started in 2014, is one of 44 in phase 3, and was the 128th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

29 of the 249 studies testing lenalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies testing lenalidomide in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to compare the safety and efficacy of Lenalidomide versus Placebo maintenance following melphalan, prednisone and velcade induction therapy in newly diagnosed multiple myeloma.

After the study is unblinded, subjects in treatment Arm A (Len 10 mg) will remain on study therapy at the Investigator's discretion and subjects in treatment Arm B (placebo), will be discontinued from study treatment. Subjects who discontinued from study treatment for any reason will enter the LTFU Phase.

Read the detailed description

The planned total number of evaluable subjects for PFS was approximately 351 (234 in the lenalidomide treatment arm; 117 in the placebo treatment arm) and the study will be conducted in European countries. However, due to the significant enrollment challenges and the changes in the NDMM treatment practices in subjects who are not eligible for transplant, such as the recent approval of Revlimid in NDMM setting, the DMC recommended to close study enrollment. Study enrollment was closed on 12 October 2015.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma
  • Lenalidomide
  • Revlimid
  • MPV
  • Melphalan
  • Prednisone
  • Velcade
  • Placebo
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:

Related to initial diagnosis and prior Melphalan Prednisone Velcade (MPV) induction therapy

  1. Previously untreated and symptomatic multiple myeloma.
  2. All 3 criteria (Durie, 2003) and at least one of the Creatinine Renal insufficiency Anemia lytic Bone lesions or osteoporosis criteria must be met.
  3. by protein electrophoresis analyses.
  4. All subjects must be treated with a minimum of 6 and a maximum of 9 cycles of MPV induction regimen, and must have achieved at least Partial Response as best overall response and maintained at Melphalan Prednisone Velcade discontinuation. If a subject achieves Complete Response prior to at least 6 cycles, the subject will be eligible, but a minimum of 6 cycles must be administered otherwise.
  5. Subjects must not have received any prior anti-myeloma chemotherapy or any agent except 6-9 cycles of induction therapy with Melphalan Prednisone Velcade.
  6. Subjects must have cytogenetic (17 p deletion, and 4;14 translocation), β-2 microglobulin and serum albumin (International Staging System) results from their initial diagnosis available at the time of screening.

    Related to the subject

  7. Must understand and voluntarily sign the document prior to the conduct of any study related assessments/procedures,
  8. Age ≥ 65 years: if \< 65 years of age, the subject must be non eligible for stem cell transplantation,
  9. performance status score ≤ 2,
  10. Able to adhere to the study visit schedules and other protocol requirements,
  11. Females of must:

    1. Have two negative pregnancy tests as verified by the study doctor prior to starting study therapy. She must agree to ongoing pregnancy testing during the course of the study, and after the end of study therapy. This applies even if the subject practices true abstinence2 from heterosexual contact.
    2. Either commit to true abstinence from heterosexual contact (which must be reviewed on a monthly basis) or agree to use, and be able to comply with, effective without interruption, 28 days prior to starting Investigational Product, during the study therapy (including dose interruptions), and for 28 days after discontinuation of study therapy.
  12. Male Subjects must:

    1. Practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female or childbearing potential while participating in the study, during dose interruptions and for at least 28 days following Investigational Product discontinuation, even if he has undergone a successful vasectomy.
    2. Agree to not donate semen during Investigational Product therapy and for 28 days after end of study therapy.
  13. All subjects must:

    1. Have an understanding that the study medication could have a potential teratogenic risk.
    2. Agree to abstain from donating blood while taking Investigational Product therapy and following discontinuation of Investigational Product therapy.
    3. Agree not to share study medication with another person.
    4. All female of childbearing potential and male subjects must be counseled about pregnancy precautions and risks of fetal exposure.

Exclusion criteria

Exclusion Criteria:

  • The presence of any of the following will exclude the subject from the study enrollment:

    1. Previous treatment with anti-myeloma therapy other than the required 6-9 cycles of Melphalan Prednisone Velcade induction therapy (does not include local radiotherapy, bisphosphonates, or a single short course of [ie, less than or equal to the equivalent of dexamethasone 40 mg/day for 4 days; such a short course of steroid treatment must not have been given within 14 days of randomization]).
    2. Subjects who didn't achieve Partial Response or better after getting at least 6 cycles of Melphalan Prednisone Velcade and at the end of Melphalan Prednisone Velcade whatever the overall response are not eligible.
    3. Prior therapy with immunomodulating or agents, or epigenetic or desoxyribonucleic acid modulating agents. Subjects who received agents are also excluded.
    4. Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
    5. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study
    6. Pregnant or lactating females.
    7. Any of the following laboratory abnormalities:

      \< 1,000/L (1.0 x 10*9/L) Untransfused count \< 50,000 cells/L (50 x 10*9/L) Serum glutamic oxaloacetic transaminase/ or serum glutamic pyruvic transaminase/alanine aminotransferase > 3.0 x Serum levels > 1.5 x upper limit of normal

    8. Renal insufficiency ( \< 30 mL/min by Cockcroft-Gault method) or actual creatinine clearance result, or renal failure requiring hemodialysis or peritoneal dialysis.
    9. Prior history of including skin cancer, other than multiple myeloma.
    10. Prior history of deep venous thrombosis or pulmonary embolus within 3 years of randomization.
    11. Subjects who are unable or unwilling to undergo anti-thrombotic therapy.
    12. Peripheral neuropathy of > Grade 2 severity according to the National Cancer Institute Version 4.0.
    13. Known positivity or active infectious hepatitis, type A, B, or C.
    14. Primary amyloidosis (immunoglobulin light chain) and myeloma complicated by amyloidosis.
    15. Prior or autologous stem cell transplantation.
    16. Significant active cardiac disease within the previous 6 months including:

      class II-IV congestive heart failure Unstable angina or angina requiring surgical or medical intervention Myocardial infarction

    17. Any condition that confounds the ability to interpret data from the study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Lenalidomide

    Treatment Arm A: lenalidomide 10 mg/day orally from Days 1 to 21; given in 28-day cycles for up to disease progression.

    Drug: Lenalidomide

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Is defined as the time from the date of randomization to the date of death due to any cause.

    Time frame: Approximately 6 years

Secondary outcomes

  1. Safety; Adverse Events (AE) [type, frequency, and severity of AEs, and relationship of AEs to investigational product (IP) SAEs, laboratory abnormalities, hospitalizations, and SPMs

    An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study.

    Time frame: Approximately 6 years

07

Study locations

73 sites
  • Centre Hospitalier EpiCURA - Clinique Louis Caty de Baudour
    Baudour, 7331, Belgium
  • AZ-VUB
    Brussels, 1090, Belgium
  • Grand Hopital de Charleroi
    Charleroi, 6000, Belgium
  • Universitair Ziehenhuis Antwerpen
    Edegem, 2650, Belgium
  • Centre Hospitalier de Jolimont-Lobbes
    La Louvière-(Haine St-Paul), 7100, Belgium
  • AZ Nikolaas
    Sint-Niklaas, 9100, Belgium
  • Cliniques Universitaires UCL de Mont-Godine
    Yvoir, 5530, Belgium
  • CH Argenteuil Victor DupouyHematologie
    Argenteuil, 95100, France
  • Centre Hospitalier de la cote basque
    Bayonne, 64109, France
  • Hopital Jean Minjoz Hematologie
    Besancon, 25000, France
  • Centre Hospitalier de Blois
    Blois Cedex, 41016, France
  • Polyclinique Bordeaux Nord Aquitaine
    Bordeaux, 33300, France
  • Hopital de Fleyriat
    Bourg en Bresse cedex, 01012, France
  • Hopital A. MorvanHematologie
    Brest cedex, 29609, France
  • CHU de la cote de Nacre
    Caen, 14000, France
  • CHRU - Hotel Dieu
    Clemont-Ferrand Cedex, 63003, France
  • Chu Estaing
    Clermont Ferrand, 63000, France
  • Centre Hospitalier Sud Francilien - Site Gilles de Corbeil
    Corbeil Essonnes, 91106, France
  • Hopital Henri Mondor
    Creteil, 94010, France
  • Centre Hospitalier
    Dunkerque, 59385, France
  • CHD Vendee
    La Roche Sur Yon, 85000, France
  • CH Hematologie
    Le Chesnay Cedex, 78157, France
  • Kremlin Bicetre
    Le Kremlin bicetre CDX, 942975, France
  • Centre Hospitalier Medecine interne
    Le Mans cedex, 72037, France
  • Centre Jean BernardOnco-Hematologie
    Le Mans, 72000, France
  • CHRU Hopital Claude Huriez
    Lile Cedax, 59037, France
  • CH - Hôpital Dupuytren
    Limoges Cedex 1, 87042, France
  • Centre Hospitalier Regional Metz-Thionville Hopital de Mercy
    Metz Cedex 03, 57038, France
  • CHU de Nimes
    Nimes Cedex 9, 30029, France
  • CH La Source Onco-Hèmatologie
    Orleans, 45000, France
  • Hopital Saint Louis
    Paris, 75010, France
  • Groupe Hospitalier Pitié- Salpétrière
    Paris, 75651, France
  • CH Perpignan - Hopital Saint-Jean
    Perpignan, 66046, France
  • Centre Hospitalier Lyon Sud
    Pierre Bénite, 69495, France
  • Centre Hospitalier de la Region d'Annecy
    Pringy, 74374, France
  • CHRU Hopital sud Medecine Interne
    Rennes cedex 02, 35056, France
  • Centre Hospitalier Yves Le Foll
    St-Brieuc cedex 1, 22027, France
  • Hopital civil
    Strasbourg, 67091, France
  • CHRU Hôpital de Hautepierre
    Strasbourg, 67098, France
  • Institut Universitaire du Cancer IUCT - Oncopole
    Toulouse Cedex, 31059, France
  • CHRU Hopital BretonneauOnco-hematologie
    Tours cedex, 37044, France
  • CHRU Hôpitaux de Brabois
    Vandoeuvre, France
  • Laiko General Hospital of Athens
    Athens, 11527, Greece
  • Alexandra General Hospital of Athens
    Athens, 11528, Greece
  • University of Patras
    Patras, 26500, Greece
  • Theagenio Anticancer Hospital of Thessaloniki
    Thessaloniki, 540 07, Greece
  • Policlinico Sant'Orsola-Malpighi
    Bologna, 40138, Italy
  • Spedali Civili Brescia
    Brescia, 25123, Italy
  • Ospedale Ferrarotto
    Catania, 95124, Italy
  • Clinica Ematologica, A.O.U. San Martino di Genova
    Genova, 16132, Italy
  • Ematologia ed Immunologia, Azienda Ospedaliera Vito Fazzi di Lecce
    Lecce, 73100, Italy
  • Unità Operativa di Oncoematologia, Ospedale di Matera
    Matera, 75100, Italy
  • U.O. di Ematologia e Trapianto di Midollo Osseo
    Milano, 20132, Italy
  • Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale
    Napoli, Campania, 80131, Italy
  • Policlinico San Matteo Universita Di Pavia
    Pavia 2, 27100, Italy
  • Ospedale Civile di Piacenza
    Piacenza, 29100, Italy
  • Arcispedale Santa Maria Nuova
    Reggio Emilia, 42100, Italy
  • Policlinico Umberto I
    Roma, 00161, Italy
  • Ospedale Sant'Eugenio
    Rome, 00144, Italy
  • IRCCS Casa Sollievo della Sofferenza
    San Giovanni Rotondo, 71013, Italy
  • Dipartimento Medicina ed Oncologia Sperimentale - Divisione Universitaria di Ematologia Azienda Ospe
    Torino, 10126, Italy
  • Ospedale Umberto I
    Torrette Di Ancona, 60020, Italy
  • A.O. Universitaria Fondazione Macchi
    Varese, 21100, Italy
  • Hospital Sant Pau
    Barcelona, 08025, Spain
  • Hospital Clinic Provincial de Barcelona
    Barcelona, 08036, Spain
  • Hospital virgen de la Arrixaca
    El Palmar (murcia), 30120, Spain
  • Hospital Virgenes de las Nieves
    Granada, 18014, Spain
  • Hospital La Princesa
    Madrid, 28006, Spain
  • Hospital Costa del Sol
    Marbella, 29603, Spain
  • Hospital Central de Asturias
    Oviedo, 33006, Spain
  • Clinica Universitaria de Navarra
    Pamplona, 31008, Spain
  • Hospital Universitario de Salamanca
    Salamanca, 37007, Spain
  • Complejo Hospitalario de Santiago
    Santiago de Compostela, 15706, Spain
08

References and documents

Publications

  • Ailawadhi S, Jacobus S, Sexton R, Stewart AK, Dispenzieri A, Hussein MA, Zonder JA, Crowley J, Hoering A, Barlogie B, Orlowski RZ, Rajkumar SV. Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J. 2018 Jul 6;8(7):67. doi: 10.1038/s41408-018-0102-7. PubMed 29980678 ↗
  • Dumontet C, Hulin C, Dimopoulos MA, Belch A, Dispenzieri A, Ludwig H, Rodon P, Van Droogenbroeck J, Qiu L, Cavo M, Van de Velde A, Lahuerta JJ, Allangba O, Lee JH, Boyle E, Perrot A, Moreau P, Manier S, Attal M, Roussel M, Mohty M, Mary JY, Civet A, Costa B, Tinel A, Gaston-Mathe Y, Facon T. A predictive model for risk of early grade >/= 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. Leukemia. 2018 Jun;32(6):1404-1413. doi: 10.1038/s41375-018-0133-x. Epub 2018 Apr 26. PubMed 29784907 ↗
  • Jain T, Sonbol MB, Firwana B, Kolla KR, Almader-Douglas D, Palmer J, Fonseca R. High-Dose Chemotherapy with Early Autologous Stem Cell Transplantation Compared to Standard Dose Chemotherapy or Delayed Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant. 2019 Feb;25(2):239-247. doi: 10.1016/j.bbmt.2018.09.021. Epub 2018 Sep 20. PubMed 30244101 ↗
  • Gambella M, Omede P, Spada S, Muccio VE, Gilestro M, Saraci E, Grammatico S, Larocca A, Conticello C, Bernardini A, Gamberi B, Troia R, Liberati AM, Offidani M, Rocci A, Palumbo A, Cavo M, Sonneveld P, Boccadoro M, Oliva S. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis. Cancer. 2019 Mar 1;125(5):750-760. doi: 10.1002/cncr.31854. Epub 2018 Dec 18. PubMed 30561775 ↗
  • Pegourie B, Karlin L, Benboubker L, Orsini-Piocelle F, Tiab M, Auger-Quittet S, Rodon P, Royer B, Leleu X, Bareau B, Cliquennois M, Fuzibet JG, Voog E, Belhadj-Merzoug K, Decaux O, Rey P, Slama B, Leyronnas C, Zarnitsky C, Boyle E, Bosson JL, Pernod G; IFM Group. Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study. Am J Hematol. 2019 Jun;94(6):635-640. doi: 10.1002/ajh.25459. Epub 2019 Apr 1. PubMed 30859608 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2014 to primary completion in Oct 2020, 77 months.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 77 months is above that.

Counting every sponsor, half of 178 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2014
First posted
Apr 11, 2014
StartActual
Apr 30, 2014
Primary completionActual
Oct 12, 2020
CompletionActual
Oct 12, 2020
Last update
Apr 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02112175
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Apr 11, 2014
Start date
Apr 30, 2014
Primary completion
Oct 12, 2020
Completion
Oct 12, 2020
Last update
Apr 14, 2021

Study contacts

Amine Bensmaine, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion